H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $47 from $44 and keeps a Buy rating on the shares. Oculis reported Q1 results and completed Phase 3 trials of OCS-01 for diabetic macular edema, with topline data expected in June 2026 and the potential to introduce the first approved topical eye drop for this large, underserved retinal disease market, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target raised to $44 from $43 at BofA
- Oculis reports Q1 EPS (49c), consensus (41c)
- Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results
- Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes
- Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing